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Effect of ascorbate on plasminogen activator inhibitor-1
expression and release from platelets and endothelial
cells in an in-vitro model of sepsis
Scott B. Swarbrecka,b,c, Dan Secora,b, Christopher G. Ellisa,c,
Michael D. Sharped, John X. Wilsone and Karel Tymla,b,c
The microcirculation during sepsis fails due to capillary
plugging involving microthrombosis. We demonstrated that
intravenous injection of ascorbate reduces this plugging,
but the mechanism of this beneficial effect remains unclear.
We hypothesize that ascorbate inhibits the release of the
antifibrinolytic plasminogen activator inhibitor-1 (PAI-1)
from endothelial cells and platelets during sepsis.
Microvascular endothelial cells and platelets were isolated
from mice. Cells were cultured and stimulated with
lipopolysaccharide (LPS), tumor necrosis factor alpha
(TNFa), or thrombin (agents of sepsis), with/without
ascorbate for 1–24h. PAI-1 mRNA was determined by
quantitative PCR. PAI-1 protein release into the culture
mediumwas measured by ELISA. In platelets, PAI-1 release
was measured after LPS, TNFa, or thrombin stimulation,
with/without ascorbate. In endothelial cells, LPS and TNFa
increased PAI-1mRNA after 6–24h, but no increase in PAI-1
release was observed; ascorbate did not affect these
responses. In platelets, thrombin, but not LPS or TNFa,
increased PAI-1 release; ascorbate inhibited this increase at
low extracellular pH. In unstimulated endothelial cells and
platelets, PAI-1 is released into the extracellular space.
Thrombin increases this release from platelets; ascorbate
inhibits it pH-dependently. The data suggest that ascorbate
promotes fibrinolysis in themicrovasculature under acidotic
conditions in sepsis. Blood Coagul Fibrinolysis 26:000–000
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Introduction
Sepsis – a systemic inflammatory response to an
infection – leads to numerous physiological abnorma-
lities, including a fibrinolytic abnormality due to elevated
plasma levels of plasminogen activator inhibitor-1 (PAI-1)
[1–3]. PAI-1 can inhibit the plasmin-mediated dissolving
of microthrombi in the microvasculature and thus contrib-
ute to disseminated intravascular coagulation. To this end,
we have shown that sepsis plugs the capillary bed, invol-
ving increased occurrence of both fibrin plaques and
platelet adhesion/aggregation in capillaries [4–6]. To
our knowledge, the role of PAI-1 in sepsis-induced capil-
lary plugging is not known.
We have reported that, in septic mice, an intravenous
injection of ascorbate delayed 6 h after the onset of sepsis
unplugs capillaries [6]. Although numerous mechanisms
could explain this beneficial effect of ascorbate [6], it is
possible that ascorbate enhances the dissolving of capil-
lary microthrombi by inhibiting PAI-1. Oxidative stress
has been implicated in the increase in both mRNA and
protein expression of PAI-1 in endothelial cells [7].
Because endothelial cells and platelets (i.e. cells in the
milieu of capillary microthrombi) can release PAI-1 into
the extracellular space [8–10], the objective of the pre-
sent study was to use simple in-vitro and ex-vivo models
of sepsis to examine whether ascorbate affects PAI-1
expression and release from these two cell types. We
hypothesized that ascorbate reduces the expression and
release of PAI-1 from endothelial cells and platelets
in sepsis.
Methods
Animal preparation
All experiments were conducted under protocols
approved by the University of Western Ontario Council
on Animal Care. Endothelial cells for in-vitro experi-
ments were obtained from male wild-type C57BL/6 mice
(age 1.5–3 months) from Charles River Laboratories
(Sherbrooke, Quebec, Canada). Preliminary experiments
indicated no sex-specific differences in platelet function;
therefore platelets for ex-vivo experiments were obtained
from male or female wild-type mice of the same strain.
Mice were anesthetized with ketamine (80 mg/kg) and
xylazine (4 mg/kg) prior to cell harvest or platelet collec-
tion. All supplies were purchased from Sigma–Aldrich
(Oakville, Ontario, Canada) unless otherwise stated.
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In-vitro model of sepsis in cultured endothelial cells
Endothelial cells were harvested from the hind limb
skeletal muscle as previously described [11,12]. We have
chosen this tissue because sepsis-induced capillary plug-
ging and the beneficial effect of ascorbate against this
plugging have been observed in the mouse skeletal
muscle [5,6]. Briefly, the muscle was excised and
digested in a collagenase solution for 30 min. The endo-
thelial cells were purified using a lectin-coated magnetic
bead immunoseparation. The cells were cultured and
used for experiments up to passage 10. For each experi-
ment, cells were grown to confluence and treated with
ascorbate (100mmol/l) for 1, 3, 6, or 24 h, concurrently
with either lipopolysaccharide (LPS) (10mg/ml) or tumor
necrosis factor alpha (TNFa) (10 ng/ml). Alternatively,
cells were treated with thrombin (0.0375 U/ml) for
3–5 min at the end of the 24-h period. We used LPS
and TNFa as conventional agents of sepsis as these
substances have been shown to initiate endotoxemia
in vivo [13,14]. The chosen dose of ascorbate results in
physiological levels of intracellular ascorbate [15].
Thrombin (0.0375 U/ml) has been used to activate plate-
lets to mimic sepsis ex vivo [16]. We have used this
concentration of thrombin in endothelial cells as an
alternative in-vitro model of sepsis. After completion
of experiments, cell supernatants were collected and
frozen, and the cells were lyzed in Tris-NaCl-Triton-
EDTA (TNTE) buffer or Trizol (Invitrogen, Burlington,
Ontario, Canada).
Ex-vivo model of sepsis in isolated platelets
Blood was collected (9 : 1) in acid citrate dextrose
solution, and platelets were isolated as detailed pre-
viously [16]. Briefly, the blood was centrifuged at 179
relative centrifugal force (rcf), and the supernatant was
retained and centrifuged at 774 rcf to pellet the platelets.
The platelet pellet was resuspended in Dulbecco’s phos-
phate-buffered saline (DPBS), divided evenly among the
control and treatment groups on the particular experi-
mental day, and stimulated with thrombin (0.0375 U/ml),
LPS (10mg/ml), or TNFa (10 ng/ml) with or without
ascorbate (100, 1000, or 10 000mmol/l). In some experi-
ments with ascorbate, we used sodium hydroxide
(NaOH) to adjust the pH of the DPBS þ ascorbate
solution to 7.4. In other experiments, we exposed plate-
lets to DPBS solution, whose pH was set to 3.8, 5.8, or 7.0
by hydrochloric acid (HCl). The platelets were incubated
at 37 8C for 10 min, then centrifuged to pellet the plate-
lets. The supernatant was retained and frozen, and the
platelet pellet homogenized in TNTE buffer or Trizol.
Plasminogen activator inhibitor-1 mRNA expression
The mRNA was isolated using the phenol–chloroform
extraction method. The isolated mRNA was purified
using DNAse I and Reverse Transcribed using Super-
script II (Invitrogen). The mRNA was quantified using
Quantifast SYBR Green (Qiagen, Mississauga, Ontario,
Canada) as directed on a Bio-Rad CFX96 thermal
cycler (Bio-Rad, Mississauga, Ontario, Canada). The pri-
mers used to detect the mRNA are as follows: PAI-1
(forward: 50-GACAGCACTGTCAGGGTCCATAG-30
and reverse: 50-GCGGTCCTCCTTCACAAAGCTC-30)
andb-actin as a housekeeping gene (forward: 50-TCGTG-
GGCCGCTCTAGGCACCA-30 and reverse: 50-GTTG-
GCCTTAGGGTTCAGGGGGG-30). The mRNA was
amplified using the following cycling protocol: 95 8C for
5 min and then 40 cycles of 95 8C for 10 s, 60 8C for 30 s, and
80 8C for 30 s.
Plasminogen activator inhibitor-1 protein expression
and release
Both intracellular PAI-1 protein (i.e. PAI-1 in cell lysates)
and PAI-1 release (i.e. PAI-1 in cell supernatants) were
quantified using the total PAI-1 ELISA kit (IMPAIKT-
TOT; Innovative Research, Novi, Michigan, USA)
according to the manufacturer’s directions.
Statistical analysis
Data are shown as mean standard error (SE). A mini-
mum of five different cell lines were used for the endo-
thelial cell experiments. A minimum of three groups of
pooled platelets were used for the platelet experiments.
Statistical analysis was performed using a repeated-
measures one-way analysis of variance (ANOVA) and
the Bonferroni multiple comparison test. Results are
significant with a P value less than 0.05.
Results
Endothelial cell plasminogen activator inhibitor-1 mRNA
and protein expression
mRNA analysis of endothelial cell PAI-1 expression
revealed that LPS and TNFa raised expression after 6
and 24 h of stimulation (Fig. 1), but not after 1 and 3 h of
stimulation (data not shown), when compared with con-
trol unstimulated cells. Ascorbate had no effect on the
expression of PAI-1 mRNA at 1–6 h, but there was a
tendency for increased PAI-1 mRNA in control and
TNFa groups at 24 h. Interestingly, the LPS or
TNFa-induced increase in mRNA seen at 6 and 24 h
did not translate into increased production of PAI-1
protein at 24 h (Fig. 2). Surprisingly, in control cells,
ascorbate increased the production of PAI-1 protein. In
LPS or TNFa-treated cells, ascorbate had no effect on
intracellular PAI-1 protein (Fig. 2).
Plasminogen activator inhibitor-1 protein release from
endothelial cells
For all control, LPS, and TNFa groups at 24 h, PAI-1
protein release was much larger than the amount of PAI-1
protein remaining in the cells (Fig. 2). Ascorbate did not
affect the PAI-1 release in any of the groups (Fig. 2).
Figure 3 shows the effect of acute stimulation of endo-
thelial cells with thrombin. Ascorbate did not affect the
PAI-1 production or release from control cells. Thrombin
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had no effect on intra-endothelial PAI-1 protein in cells
treated with either vehicle or ascorbate for 24 h, nor on
PAI-1 protein release from these cells (Fig. 3). Thrombin
did not affect the increased intracellular PAI-1 in control
cells treated with ascorbate (Fig. 3).
Plasminogen activator inhibitor-1 protein release from
platelets
There was experiment-to-experiment variability in the
number of platelets collected. We tested randomly
selected aliquots of platelets to determine the platelet
counts. The mean number of platelets added per treat-
ment (100ml) was 29.9 106 3.9 106 (n¼ 10). In gen-
eral, this variability resulted in different levels of
intracellular and released PAI-1 protein in control plate-
lets among experiments. Because of this variability, the
results from treated and control platelets were paired for
each experiment.
Figure 4 shows that neither LPS nor TNFa affected
intracellular and released PAI-1 protein levels when
compared to the control unstimulated platelets. We then
tested whether thrombin would initiate platelet PAI-1
release. As each treatment group had both control and
thrombin only treatments, we pooled these results and
observed that the platelets contained 0.38 0.06 ng/ml of
PAI-1 intracellularly and spontaneously released
0.11 0.01 ng/ml PAI-1. Upon stimulation with throm-
bin, release of PAI-1 from the platelets significantly
increased with 0.29 0.05 ng/ml remaining intracellularly
and 0.32 0.06 ng/ml released (P< 0.05 compared to
control, n¼ 21 per group).
Effect of pH and ascorbate on platelet plasminogen
activator inhibitor-1 protein release
As thrombin-induced platelet PAI-1 release, our next
objective was to determine whether ascorbate affected
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Increases in PAI-1 mRNA expression after 6 and 24 h of endotoxin treatment were not altered by ascorbate (Asc). Isolated endothelial cells were
treated with either LPS (10mg/ml) or TNFa (10 ng/ml) for 6 or 24 h as indicated. Some cells were also treated with 100mmol/l Asc concurrently.
Total cell mRNA was extracted, reverse-transcribed, and PAI-1 mRNA was quantified using qPCR. At 6 (a) and 24 h (b), there was a significant
increase in PAI-1 expression with both LPS and TNFa treatment. Asc did not appear to have an effect on this increase in PAI-1 expression. ()
P<0.05 compared to control (n¼4–7 different cell lines per treatment). LPS, lipopolysaccharide; PAI-1, plasminogen activator inhibitor-1; qPCR,
quantitative PCR; TNFa, tumor necrosis factor alpha.
Fig. 2
Intracellular PAI-1
Asc Asc Asc
0
250
500
750
1000
Control
LPS
TNF
*
T
ot
al
 P
A
I-
1 
(n
g/
m
l)
Released PAI-1
Asc Asc Asc
0
250
500
750
1000
Control
LPS
TNF
T
ot
al
 P
A
I-
1 
(n
g/
m
l)
(a) (b) 
Lipopolysaccharide (LPS) or TNFa did not alter the PAI-1 production or release in endothelial cells. Endothelial cells were treated with LPS
(10mg/ml) or TNFa (10 ng/ml) for 24 h, the supernatant was collected, and the cells were lyzed. The PAI-1 content in the cells and released in the
supernatant was quantified using an ELISA. Ascorbate (Asc) treatment alone for 24 h significantly increased the PAI-1 production in the endothelial
cells (a). Co-treatment with either LPS or TNFa eliminated the observed increase in PAI-1 protein. No treatment altered the PAI-1 release into the
supernatant (b). () P<0.05 compared to control (n¼4 cell lines per group). PAI-1, plasminogen activator inhibitor-1; TNFa, tumor necrosis factor
alpha.
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this release. Using a 100mmol/l concentration of ascor-
bate, there was no effect on platelet concentration or
release of PAI-1 (Fig. 5a and b); however, using a dose of
1000mmol/l, ascorbate partially inhibited its release
(Fig. 5c and d). While a 100mmol/l concentration of
ascorbate had no effect on the extracellular pH, ascorbate
at 1000mmol/l reduced the pH to 7.0. In a parallel
experiment, we prepared DPBS solution in which the
pH was set to 7.0 by HCl. In this experiment, the
thrombin-induced platelet PAI-1 release was inhibited;
this inhibition was similar to that of ascorbate at
1000mmol/l (Fig. 5c and d). Ascorbate administered at
a concentration of 10 000mmol/l (pH of DPBS þ ascor-
bate solution reduced to 3.8) potently inhibited the
thrombin-induced platelet PAI-1 release (Fig. 5e and
f). To test whether this inhibition was pH-sensitive,
we adjusted the pH of the DPBS þ ascorbate solution
to 7.4 using NaOH. Under these conditions, the inhibi-
tory effect of ascorbate was abolished (PAI-1 released by
thrombin alone: 181.2 33.2% of release by control pla-
telets; PAI-1 released by thrombin þ ascorbate:
202.5 19.5% of control, n¼ 4 per group, P¼ 0.60). In
the parallel experiment (pH set to 3.8 by HCl), the
platelet PAI-1 release was similarly inhibited as by
10 000mmol/l ascorbate (Fig. 5e and f).
Because of the similarity between the effects of ascorbate
and HCl, we tested whether the inhibition of thrombin-
induced PAI-1 release from platelets was pH-dependent.
Figure 6 shows this dependency.
Discussion
We previously showed that an intravenous bolus of
ascorbate reduces capillary plugging, leading to improved
4 Blood Coagulation and Fibrinolysis 2015, Vol 00 No 00
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Short-term thrombin has no effect on the release of PAI-1 protein from endothelial cells. Endothelial cells previously treated with ascorbate (Asc) or
fresh media for 24 h were treated with thrombin (0.0375 U/ml) for 5 min, then the supernatant was collected and the cells lyzed. Thrombin had no
effect on the release of PAI-1 into the supernatant (b). Ascorbate treatment significantly increased the PAI-1 production intracellularly (a). ()
P<0.05 compared to control (n¼5 cell lines per group). PAI-1, plasminogen activator inhibitor-1.
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Plasminogen activator inhibitor-1 (PAI-1) release by platelets is not induced by LPS or TNFa. Platelets were isolated from whole mouse blood,
stimulated with LPS (10mg/ml) or TNFa (10 ng/ml) for 10 min, then the supernatant and platelet pellets were collected and subjected to ELISA.
Neither LPS nor TNFa treatment affected intraplatelet PAI-1 protein expression (a) or caused release of PAI-1 protein from the platelets into the
supernatant (b) (n¼6 platelet isolations per group). LPS, lipopolysaccharide; PAI-1, plasminogen activator inhibitor-1; TNFa, tumor necrosis factor
alpha.
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survival in sepsis [4–6]. The present study used simpli-
fied in-vitro and ex-vivo models of sepsis to examine the
effect of ascorbate on PAI-1 production and release from
endothelial cells and platelets, that is, cells found in the
milieu of developing capillary microthrombi. We show
that PAI-1 production and release from endothelial cells
and platelets is not affected by a low-dose ascorbate
(100mmol/l). However, increasing concentrations of
ascorbate may inhibit PAI-1 release from platelets in a
pH-dependent manner.
Plasminogen activator inhibitor-1 mRNA expression in
endothelial cells
Our finding that 1 or 3 h LPS/TNFa does not alter
endothelial cell PAI-1 mRNA contrasts with the reported
early PAI-1 increase after LPS treatment [17]. However,
the increased PAI-1 mRNA observed at 6 and 24 h mirrors
that of the previous studies [17,18]. It is possible that
interspecies differences between mouse and human cells
may be responsible for the delayed response to LPS.
Indeed, it has been reported that humans have a mark-
edly increased sensitivity to LPS compared to mice, and
that interspecies differences in sensitivity to infections
can have profound effects on survival [13,19]. Ascorbate
did not appear to have any effect on PAI-1 mRNA
expression after 1–6 h of treatment. At 24 h, ascorbate
tended to increase the PAI-1 mRNA expression in the
control cells and in TNFa-treated cells (Fig. 1b).
Plasminogen activator inhibitor-1 protein expression
and release from endothelial cells
Because the amount of PAI-1 released from endothelial
cells was much larger than PAI-1 remaining in the cells
(Fig. 2), it appears that these cells contribute significantly
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Effects of ascorbate (Asc) and pH on thrombin-induced PAI-1 release from platelets. Isolated platelets were treated with ascorbate (100mmol/l,
panels a and b; 1000mmol/l, panels c and d; or 10 000mmol/l, panels e and f) for 3 min and then by thrombin (0.0375 U/ml) for 10 min. The
supernatant and platelet pellets were collected and subjected to ELISA. Thrombin induced a significant release of PAI-1 from the platelets into the
supernatant (b, d, and f). Ascorbate at 1000 or 10 000mmol/l prevented the thrombin-induced PAI-1 release (d and f). Panels c–e and f also show
results from experiments in which we used HCl to set the pH of extracellular fluid to 7.0 or 3.8 (i.e. bars labeled by pH 7.0 or pH 3.8). () P<0.05
compared to control unstimulated platelets, (#) P<0.05 compared to thrombin-stimulated platelets [n¼4 platelet isolations per group (a, b), n¼4
platelet isolations per group (c, d), and n¼3–6 platelet isolations per group (e, f)]. PAI-1, plasminogen activator inhibitor-1.
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to the total PAI-1 within the vasculature. LPS, TNFa, and
thrombin did not affect intra-endothelial and released
PAI-1 protein (Figs. 2 and 3). This lack of effect contrasts
with previous studies in human umbilical vein endothelial
cells, in which significant increases in PAI-1 protein pro-
duction were observed [17,18]. Given the interspecies
variability, it is possible that the expression of PAI-1 in
mouse cells differs from that of the human cells.
Effect of ascorbate on plasminogen activator inhibitor-1
protein expression in endothelial cells
The tendency of ascorbate to increase PAI-1 mRNA in
control cells translated to increased PAI-1 protein pro-
duction in these cells. LPS and TNFa inhibited this
increased production (Fig. 2a). However, increased intra-
endothelial PAI-1 did not result in increased PAI-1
release into the extracellular space (Fig. 2b). The mech-
anism of this phenomenon is not clear. We speculate that
ascorbate may increase the stability of PAI-1, thus enhan-
cing the total content [20].
Overall, the long period required for ascorbate to induce
any changes in PAI-1 content in endothelial cells (e.g.
24 h) does not lend itself to explain any acute in-vivo
effects of ascorbate on fibrinolysis [4–6]. Thus, in the
septic microvasculature, restoring capillary blood flow
over the short period of 1 h following ascorbate admin-
istration [6] may not be explained by ascorbate’s inhi-
bition of PAI-1 release from endothelial cells.
Effect of ascorbate and pH on plasminogen activator
inhibitor-1 release from platelets
Consistent with our report that LPS and TNFa do not
affect platelet aggregation [16], LPS and TNFa did not
affect PAI-1 release from platelets (Fig. 4). This finding
agrees with the reports of lack of effect of LPS [21] and
TNFa [22] in platelets isolated from mice, though others
have observed spontaneous platelet activation upon LPS
stimulation [23]. We note that these conflicting studies
were conducted with platelets from species other than
mice, suggesting that interspecies differences may be
involved in the different responses. It is also possible that
neither LPS nor TNFa directly stimulates platelets, but
rather induces the production of other signaling mol-
ecules (i.e. thrombin) that ultimately activate platelets
[24]. The present ex-vivo model may lack the cells
necessary for the production of these signaling molecules.
The observed PAI-1 release from platelets following
short-term stimulation with thrombin is consistent with
the literature [9,10]. Ascorbate at a concentration of
100mmol/l did not alter the release of PAI-1 from plate-
lets. This is in contrast to our previous report that
ascorbate reduces the rate of thrombin-induced aggrega-
tion [16]. It is possible that we were unable to observe a
reduction in the rate of PAI-1 release due to our inability
to measure the PAI-1 content in real time.
Treatment with 1000 and 10 000mmol/l ascorbate at an
unbuffered pH 7.0 and 3.8, respectively, inhibited the
thrombin-induced platelet PAI-1 release (Fig. 5).
Critically ill patients can develop severe acidosis, when
the blood pH drops below 6.8 [25], and this level may be
as low as 6.0 in localized regions, particularly during
ischemia [26]. Thus, pH values in patients fall within
the range of pH in the present study. Importantly, when
the pH of ascorbate solution (10 000mmol/l) was adjusted
to 7.4, the inhibition of PAI-1 release by ascorbate was
abolished, indicating the inhibition is pH-dependent.
Consistently, we demonstrated that the thrombin-
induced platelet PAI-1 release can be inhibited by low-
ering the pH of the extracellular solution (Fig. 6). Our
finding of a potential pH-dependent effect of ascorbate
agrees with the report that thrombin-induced platelet
adhesion is reduced by approximately 25% at pH 7.0 and
50% at pH 6.5 [26].
Could the reduced plugging in septic capillaries by
ascorbate injection be partially explained in terms of
the pH-dependent inhibition of PAI-1 release from pla-
telets? Our preliminary experiments in sham mice
injected with ascorbate (10 mg/kg) demonstrated a
decreased blood pH from 7.2 to 7.0 at 5 min postinjection.
At this pH, our observed inhibition of thrombin-induced
PAI-1 release by ascorbate may just begin to be effective
(Fig. 5d). When ascorbate is used at a higher dose (e.g.
200 mg/kg [27,28]), this effectiveness may increase. Con-
sidering that blood pH during sepsis may be acidotic, we
speculate that treatment of septic mice with ascorbate
may further lower the pH, resulting in inhibition of PAI-1
release by ascorbate in a pH-dependent manner.
In conclusion, we have confirmed the presence and
release of PAI-1 protein by both endothelial cells and
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Thrombin-induced release of PAI-1 from platelets is pH-dependent.
Isolated platelets were treated with thrombin (0.0375 U/ml) for 10 min
in Dulbecco’s phosphate-buffered saline (DPBS, control bar), or in
DPBS solution, the pH of which was set to 3.8, 5.8, or 7.0 by HCl.
The thrombin-induced PAI-1 release was reduced with lowered pH
(n¼3–4 platelet isolations per group). HCl, hydrochloric acid; PAI-1,
plasminogen activator inhibitor-1.
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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platelets – two cell types in close proximity to a devel-
oping intravascular thrombus during sepsis. Although
ascorbate did not directly affect thrombin-induced
PAI-1 release from platelets, it reduced the release
indirectly through a pH-dependent mechanism.
Acknowledgements
We thank Dr Fuyan Li for technical help.
Grant numbers and sources of support: This work was
supported by the Heart and Stroke Foundation of Ontario
(grant T6325 to K.T.), the Canadian Institutes for Health
Research (grant MOP 102504 to C.G.E.), Ontario Gradu-
ate Scholarship in Science and Technology (S.S. and D.S.
salaries), and Lawson Health Research Institute Internal
Research Fund (S.S. and D.S. salaries).
Conflicts of interest
There are no conflicts of interest.
References
1 Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular
coagulation. J Thromb Thrombolysis 2003; 16:43–47.
2 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med
1999; 341:586–592.
3 Trzeciak S, Jones AE, Shapiro NI, Pusateri AE, Arnold RC, Rizzuto M, et al.
A prospective multicenter cohort study of the association between global
tissue hypoxia and coagulation abnormalities during early sepsis
resuscitation. Crit Care Med 2010; 38:1092–1100.
4 Tyml K, Li F, Wilson JX. Delayed ascorbate bolus protects against
maldistribution of microvascular blood flow in septic rat skeletal muscle.
Crit Care Med 2005; 33:1823–1828.
5 Tyml K, Li F, Wilson JX. Septic impairment of capillary blood flow requires
nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide
synthase and is rapidly reversed by ascorbate through an endothelial nitric
oxide synthase-dependent mechanism. Crit Care Med 2008; 36:2355–
2362.
6 Secor D, Li F, Ellis CG, Sharpe MD, Gross PL, Wilson JX, et al. Impaired
microvascular perfusion in sepsis requires activated coagulation and P-
selectin-mediated platelet adhesion in capillaries. Intensive Care Med
2010; 36:1928–1934.
7 Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, Bernhardt F,
Gaertner R, Lockhart BP, et al. Nox4 mediates the expression of
plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human
endothelial cells. Thromb Res 2009; 124:439–446.
8 Sagripanti A, Morganti M, Carpi A, Cupisti A, Nicolini A, Barsotti M, et al.
Uremic medium increases cytokine-induced PAI-1 secretion by cultured
endothelial cells. Biomed Pharmacother 1998; 52:298–302.
9 Nylander M, Osman A, Ramstrom S, Aklint E, Larsson A, Lindahl TL. The
role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis
and secretion by human platelets. Thromb Res 2012; 129:e51–e58.
10 Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets retain high
levels of active plasminogen activator inhibitor 1. PLoS One 2011;
6:e26762.
11 Bolon ML, Kidder GM, Simon AM, Tyml K. Lipopolysaccharide reduces
electrical coupling in microvascular endothelial cells by targeting
connexin40 in a tyrosine-, ERK1/2-, PKA-, and PKC-dependent manner.
J Cell Physiol 2007; 211:159–166.
12 McKinnon RL, Bolon ML, Wang HX, Swarbreck S, Kidder GM, Simon AM,
et al. Reduction of electrical coupling between microvascular endothelial
cells by NO depends on connexin37. Am J Physiol Heart Circ Physiol
2009; 297:H93–H101.
13 Fink MP. Animal models of sepsis. Virulence 2013; 5:143–153.
14 Freise H, Bruckner UB, Spiegel HU. Animal models of sepsis. J Invest Surg
2001; 14:195–212.
15 Wu F, Tyml K, Wilson JX. Ascorbate inhibits iNOS expression in endotoxin-
and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett
2002; 520:122–126.
16 Secor D, Swarbreck S, Ellis CG, Sharpe MD, Tyml K. Ascorbate reduces
mouse platelet aggregation and surface P-selectin expression in an ex vivo
model of sepsis. Microcirculation 2013; 6:502–510.
17 Perez-Ruiz A, Montes R, Velasco F, Lopez-Pedrera C, Antonio Paramo J,
Orbe J, et al. Regulation by nitric oxide of endotoxin-induced tissue factor
and plasminogen activator inhibitor-1 in endothelial cells. Thromb Haemost
2002; 88:1060–1065.
18 Ruan QR, Zhang WJ, Hufnagl P, Kaun C, Binder BR, Wojta J. Anisodamine
counteracts lipopolysaccharide-induced tissue factor and plasminogen
activator inhibitor-1 expression in human endothelial cells: Contribution of
the NF-kappa b pathway. J Vasc Res 2001; 38:13–19.
19 McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B. Species
differences in kupffer cells and endotoxin sensitivity. Infect Immun 1984;
45:278–280.
20 Lang IM, Schleef RR. Calcium-dependent stabilization of type I
plasminogen activator inhibitor within platelet alpha-granules. J Biol Chem
1996; 271:2754–2761.
21 Rumbaut RE, Bellera RV, Randhawa JK, Shrimpton CN, Dasgupta SK,
Dong JF, et al. Endotoxin enhances microvascular thrombosis in mouse
cremaster venules via a TLR4-dependent, neutrophil-independent
mechanism. Am J Physiol Heart Circ Physiol 2006; 290:H1671–H1679.
22 Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD.
Antithrombotic activity of TNF-alpha. J Clin Invest 2003; 112:1589–1596.
23 Casarin AL, Lopes-Pires ME, Morganti RP, Antunes E, Marcondes S.
Reactive oxygen and nitrogen species modulate the ex-vivo effects of LPS
on platelet adhesion to fibrinogen. Life Sci 2011; 89:773–778.
24 Kerrigan SW, Cox D. Platelet-bacterial interactions.Cell Mol Life Sci 2010;
67:513–523.
25 Paz Y, Zegerman A, Sorkine P, Matot I. Severe acidosis does not predict
fatal outcomes in intensive care unit patients: A retrospective analysis.
J Crit Care 2014; 29:210–213.
26 Etulain J, Negrotto S, Carestia A, Pozner RG, Romaniuk MA, D’Atri LP, et al.
Acidosis downregulates platelet haemostatic functions and promotes
neutrophil proinflammatory responses mediated by platelets. Thromb
Haemost 2012; 107:99–110.
27 Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Puri P, Massey HD, et al.
Attenuation of sepsis-induced organ injury in mice by vitamin C. JPEN J
Parenter Enteral Nutr 2014; 38:825–838.
28 Fisher BJ, Kraskauskas D, Martin EJ, Farkas D, Wegelin JA, Brophy D, et al.
Mechanisms of attenuation of abdominal sepsis induced acute lung injury
by ascorbic acid. Am J Physiol Lung Cell Mol Physiol 2012; 303:L20–32.
Ascorbate effect on plasminogen activator inhibitor-1 Swarbreck et al. 7
